NDA 212155 · Ge Healthcare
Cerianna
Fluoroestradiol F-18 · Intravenous · Radioactive Diagnostic Agent
NovelLast checked: Nov 20, 2026Latest source record: May 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 20, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
11
0 Phase 3, 2 recruiting
FAERS reports
22
3 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 12, 2026.
CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. CERIANNA is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. ( 1 ) Limitations of Use Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR). ( 1 , 5.1 ) Limitations of Use Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).
Mechanism: Fluoroestradiol F 18 binds ER. The following binding affinity: Kd = 0.13 ± 0.02 nM, Bmax = 1901 ± 89 fmol/mg, and IC 50 = 0.085 nM, was determined in an ER-positive human breast cancer cell line (MCF-7).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CERIANNA · FLUOROESTRADIOL F-18 50ML (4-100mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluoroestradiol F-18" as an intervention, any sponsor and status, largest first.
- FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine TherapyActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02398773 · 99 participants (planned) · Start May 4, 2016 · Primary completion Dec 31, 2026
Drug: F-18 16 Alpha-Fluoroestradiol · For: HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive and 1 more
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 25 sites in all
University of WashingtonAcademic, hospital or other
NCT07112053 · 40 participants (planned) · Start Nov 17, 2025 · Primary completion Jul 31, 2028
Drug: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine; Capecitabine and 5 more · For: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma
Sites: Seattle, Washington
University of WashingtonAcademic, hospital or other
NCT02149173 · 29 participants · Start Sep 15, 2010 · Primary completion Dec 27, 2018
Drug: F-18 16 Alpha-Fluoroestradiol; Fludeoxyglucose F-18 · For: Estrogen Receptor Positive; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7
Sites: Seattle, Washington
- Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular CarcinomaCompleted
Asan Medical CenterAcademic, hospital or other
NCT05960201 · 23 participants · Start Aug 10, 2023 · Primary completion Aug 20, 2024
Drug: [18F]fluoroestradiol (FES) · For: Carcinoma, Lobular
Sites: Seoul, South Korea
City of Hope Medical CenterAcademic, hospital or other
NCT06260033 · 18 participants (planned) · Start Jul 23, 2024 · Primary completion Oct 29, 2027
Drug: F-18 16 Alpha-Fluoroestradiol · For: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; Metastatic Breast Carcinoma
Sites: Duarte, California; Irvine, California
University of WashingtonAcademic, hospital or other
NCT01720602 · 15 participants · Start Nov 2012 · Primary completion Mar 2015
Drug: vorinostat; anastrozole and 2 more · For: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Sites: Seattle, Washington
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor TherapyCompleted
University of WashingtonAcademic, hospital or other
NCT01153672 · 8 participants · Start Nov 2010 · Primary completion Jul 2012
Drug: vorinostat; anastrozole and 2 more · For: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Sites: Seattle, Washington
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
NCT02374931 · 3 participants · Start Apr 2015 · Primary completion Jul 2017
Drug: F-18 16 Alpha-Fluoroestradiol · For: Deep Fibromatosis/Desmoid Tumor; Familial Adenomatous Polyposis
Sites: Nashville, Tennessee
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event14
- false negative investigation result5
- drug ineffective4
- inappropriate release of product for distribution2
- product with quality issue administered2
- radioisotope scan abnormal2
- seizure2
- burning sensation1
- false negative radioisotope investigation result1
- false positive investigation result1
- false positive radioisotope investigation result1
- gait disturbance1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Ge Healthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.